| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | selpercatinib (Retsevmo®) |
| Formulation | 40 mg and 80 mg tablet |
| Reference number | 5048 |
| Indication | Treatment of adults with advanced RET fusion positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/05/2022 |
| NICE guidance | TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer |